peripheral vascular diseases

systematic review meta-analysis network meta-analysis

Select cell-based therapies cholesterol lowering interventionanticoagulantantiplatelets drugantithromboticsantioxydantsExercise Therapyvasodilators therapy uncoded clinical condition ***All type of patientDiabetic patients       anti-agrégantanticoagulantantioxydantantivitamins Kcolestipol-niacinExercise TherapyFibratesgene transferheparinplatelet aggregation inhibitorsprobucolstatinssympathectomie avec chirurgieVasodilator Agentsvitamine E atorvastatinsimvastatinbezafibratevariousacenocoumarolaspirinbuflomedilcilostazolclopidogreldipyridamolExercise Therapyginko bilobaketanserinenaftidrofurylniacinpentoxifyllinepicotamideprobucolsuloctidilticagrelorticlopidineUFHvitamin ewarfarin vs placebo or controlvs aspirinvs prostaglandine      

Filter

Group by Group by... nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition MA  in first nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in second nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in third	Description Synopsis Comparison Treatments Patients Characteristics Method Risk of bias References None Tools Indexation					Results Global trial result Main results All results All result tag NCT results	All cause death (92)myocardial infarction (fatal and non fatal) (32)Non fatal stroke (28)Vascular death (28)Amputation (27)Treatment related complication (25)Non fatal MI (25)Vascular events (24)cardiovascular events (20)Fatal MI (18)Fatal stroke (17)Fatal bleeding (16)Non cerebral major bleeding (15)Bleeding (12)Major bleeding (11)Minor bleeding (10)stroke (fatal and non fatal) (7)Cardiovascular death (5)Revascularization (3)Infection (3)Haemmorhagic stroke (2) Options Numeric bar chart forest plot medians
Trial	Studied trt	Control trt	patients	tags	ROB	Trial result	All cause death	myocardial infarction (fatal and non fatal)
anticoagulant
not classified
Kretschmer, 1992	phenprocoumon	contrôle				-
warfarin
Johnson, 2002	warfarin	contrôle				-
Sarac, 1998	warfarin	contrôle				-
antioxydants
not classified
POPADAD (antioxydant), 2008	combination	placebo			Low risk of bias	negative
vitamin e
Livingstone, 1958		placebo				-
Hamilton, 1953		placebo				-
antiplatelets drug
aspirin
Schoop, 1983	aspirin	placebo			Low risk of bias	-
Hess, 1985	aspirin	placebo				-
Munich A, 1975	aspirin	placebo			Low risk of bias	-
Munich B, 1975	aspirin	placebo			Low risk of bias	-
CLIPS, 2007	aspirin	placebo			Low risk of bias	suggesting
clopidogrel
CAPRIE (PAD subgroup), 1996	clopidogrel	aspirin			Low risk of bias	suggesting
dipyridamol
Hess (2), 1985	aspirin + dipyridamol	placebo			Low risk of bias	-
Schoop (2), 1983	aspirin + dipyridamol	placebo			Low risk of bias	-
VA study, 1986	aspirin + dipyridamol	placebo			Low risk of bias	-
ketanserine
PACK, 1996	ketanserine	placebo			Low risk of bias	-
Walden, 1991	ketanserine	placebo			Low risk of bias	-
Thulesius, 1987	ketanserine	placebo			Low risk of bias	-
picotamide
ADEP, 1993	picotamide	placebo			Low risk of bias	-
Neirotti, 1994	picotamide	placebo			Low risk of bias	-
Coto, 1989	picotamide	placebo			Low risk of bias	-
suloctidil
Adriaensen, 1976	suloctidil	placebo			Low risk of bias	-
Verhaeghe, 1981	suloctidil	placebo			Low risk of bias	-
Jones, 1982	suloctidil	placebo			Low risk of bias	-
Holm, 1984	suloctidil	placebo			Low risk of bias	-
ticagrelor
EUCLID, 2016        NCT	ticagrelor	clopidogrel			Low risk of bias	-
ticlopidine
EMATAP, 1993	ticlopidine	placebo			Low risk of bias	-
Katsumara, 1982	ticlopidine	placebo			Low risk of bias	-
Aukland, 1982	ticlopidine	placebo			Low risk of bias	-
Stiegler, 1984	ticlopidine	placebo			Low risk of bias	-
Ellis, 1986	ticlopidine	placebo			Low risk of bias	-
Cloarec, 1986	ticlopidine	placebo			Low risk of bias	-
Arcan, 1988	ticlopidine	placebo			Low risk of bias	-
Balsano, 1989	ticlopidine	placebo			Low risk of bias	-
STIMS, 1990	ticlopidine	placebo			Low risk of bias	-
Hurlow, 1980	ticlopidine	placebo			Low risk of bias	-
Krause, 1980	ticlopidine	placebo			Low risk of bias	-
various
CRAMPS, 2000	cloricromene	placebo			Low risk of bias	-
antithrombotics
not classified
Goldman, 1984		contrôle				-
Clyne, 1987		contrôle				-
Donaldson, 1985		contrôle				-
Green, 1982		contrôle				-
Kohler , 1984		contrôle				-
McCollum, 1991		contrôle				-
Kretschmer, 1992	phenprocoumon	contrôle				-
Calabro, 1993	LMWH	placebo				-
Mannarino, 1991	LMWH	placebo				-
De Smit, 1987	phenprocoumon	placebo				-
Edmondson, 1994		HBPM				-
acenocoumarol
APIC, 1989	acenocoumarol	placebo				-
aspirin
Lassila R, 1991	aspirin	contrôle				-
CLIPS, 2007	aspirin	placebo			Low risk of bias	suggesting
BOA, 2000	aspirin					-
ticlopidine
Becquemin, 1997	ticlopidine	contrôle				-
UFH
Antonicelli, 1999	HNF	placebo				-
Tesi, 1989	HNF	placebo				-
warfarin
Johnson, 2002	warfarin	contrôle				-
Sarac, 1998	warfarin	contrôle				-
cell-based therapies
not classified
RAVE (Rajagopalan), 2003	AdVEGF121	placebo			Low risk of bias	-
DELTA (Grossman), 2007	Del-1	placebo			Low risk of bias	-
Kusumanto, 2006	phVEGF165	placebo			Low risk of bias	-
TRAFFIC (Lederman), 2002	rFGF-2	placebo			Low risk of bias	-
Makinen, 2002	VEGF gene	placebo			Low risk of bias	-
cholesterol lowering intervention
atorvastatin
Mohler III, 2003	atorvastatin	placebo	Peripheral Arterial Disease		Exploratory	-
bezafibrate
LEADER trial, 2000	bezafibrate	placebo	Peripheral Arterial Disease		Low risk of bias	-
niacin
CLAS, 1987	colestipol-niacin	placebo	Peripheral Arterial Disease		Exploratory	-
probucol
PQRST, 1994	probucol	placebo	Peripheral Arterial Disease		Exploratory	-
simvastatin
HPS (sub group), 2002	simvastatin	placebo	Peripheral Arterial Disease		Low risk of bias	-
Mondillo, 2003	simvastatin	placebo	Peripheral Arterial Disease		Exploratory	-
Aronow , 2003	simvastatin	placebo	Peripheral Arterial Disease		Exploratory	-
Exercise Therapy
Exercise Therapy
Gelin, 2001	Exercise Therapy	Control				-
Mannarino E, 1991	Exercise Therapy	Control				-
Dahllof AG, 1974	Exercise Therapy	Control				-
Hiatt WR, 1990	Exercise Therapy	Control				-
Hiatt WR, 1994	Exercise Therapy	Control				-
Larsen OA, 1966	Exercise Therapy	Control				-
Tisi PV, 1997	Exercise Therapy	Control				-
Holm J, 1973	Exercise Therapy	Control				-
Fowler, 2002	Exercise Therapy	Control				-
Gardner, 2001	Exercise Therapy	Control				-
vasodilators therapy
not classified
Barnes RW, 1977	sympathectomie	contrôle				-
Satiani B, 1982	sympathectomie	contrôle				-
buflomedil
LIMB, 2008	buflomedil	placebo			Low risk of bias	suggesting
Diamantopoulos, 2001	buflomédil	placebo				-
cilostazol
Beebe, 1999	cilostazol	placebo				-
Dawson, 1998	cilostazol	placebo				-
Money, 1998	cilostazol	placebo				-
Strandness, 2002	cilostazol	placebo				-
Dawson (cilostazol), 2000	cilostazol	placebo				-
Elam, 1998	cilostazol	placebo			Low risk of bias	-
Otsuka 21-95-201	cilostazol	placebo			Low risk of bias	-
ginko biloba
Bauer, 1984	ginko biloba	placebo				-
Peters, 1998	ginko biloba	placebo				-
naftidrofuryl
Meehan, 1982	naftidrofuryl IV	control				-
NIQOL germany, 1999	Naftidrofuryl	placebo				-
Clyne, 1980	naftidrofuryl	placebo				-
NIQOL belgium, 2001	naftidrofuryl	placebo				-
NCIS, 2001	naftidrofuryl	placebo				-
Testart, 1994	naftidrofuryl IV	placebo				-
D'Hooge D, 2001	naftidrofuryl IV	placebo				-
Negus, 1987	naftidrofuryl IV	prostacyclin				-
pentoxifylline
Dawson (pentoxifylline), 2000	pentoxifylline	placebo				-
APIC, 1989	pentoxifylline	placebo				-
Donaldson, 1984	pentoxifylline	placebo				-
Porter, 1982	pentoxifylline	placebo				-
Belcaro, 2002	pentoxifylline	placebo				-